News

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Media Contact

Stephen Schultz
VP Investor Relations (U.S.)
T: 917-280-2424 / 401 500 6570
sschultz@gwpharm.com
 

Recent Press Releases

Nov 06, 2003
GW Pharmaceuticals plc (“GW”) and Bayer Healthcare AG (“Bayer”) announce that they have extended their marketing agreement for Sativex®, GW’s cannabis-based medicinal extract product, to the Canadian market.
Jun 27, 2003
GW is pleased to announce that it is raising approximately £20 million before expenses through a placing for cash of 9,904,395 new GW ordinary shares at 200 pence per share.
May 21, 2003
GW Pharmaceuticals plc (“GW”) and Bayer AG (“Bayer”) have entered into an exclusive marketing agreement for GW’s cannabis-based medicinal extract product, to be marketed under the Sativex® brand name.
Apr 16, 2003
GW announces the appointment of Hans Schram as a non-executive director with immediate effect. Mr Schram has over 20 years experience in global pharmaceutical business development and marketing.
Mar 12, 2003
GW Pharmaceuticals plc, the company developing a portfolio of non-smoked cannabis-based prescription medicines, announces that Professor Roger Pertwee, Professor of Neuropharmacology at the University of Aberdeen, h
Mar 04, 2003
GW announces that the regulatory dossier for the Company’s first cannabis-based prescription medicine has been submitted to the UK Medicines Control Agency as planned.
Feb 03, 2003
GW notes recent media comments relating to its commercialisation discussions.
Jan 21, 2003
GW Pharmaceuticals plc, the company developing a portfolio of non-smoked, cannabis-based prescription medicines, has established an extensive research collaboration with Professor Raphael Mechoulam, from the Hebrew
Jan 15, 2003
GW Pharmaceuticals plc, the company licensed by the UK Home Office to work with cannabis and a range of controlled drugs for medical research purposes, announces its preliminary results for the year ended 30 Septemb